We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesArcellx Inc

Arcellx Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-06-18T21:33:41.328978Z
Market Cap
6724.01M

Momentum Score

…

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
47.86
Low
115.13
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
22.29M
Revenue Per Share
0.40
Gross Profit TTM
-135.32M
Debt / Equity
0.24
ROE
-53.42%
Net Debt
16.00M
ROCE
-40.95%
Diluted EPS TTM
-4.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -228.87M -105.28M -70.03M -188.68M -64.97M
Net income -228.93M -107.35M -70.69M -186.10M -63.93M
Selling general administrative 117.76M 88.41M 66.35M 41.70M 18.14M
Selling and marketing expenses - - 0.00M - -
Gross profit 15.61M 102.75M 110.32M - -
Reconciled depreciation 6.68M 5.19M 1.73M 1.32M 1.04M
Ebit -204.65M -104.25M -66.19M -191.26M -66.06M
Ebitda -197.97M -99.06M -64.14M -186.96M -65.02M
Depreciation and amortization 6.68M 5.19M 2.04M 4.30M 1.04M
Operating income -253.08M -137.57M -89.88M -191.26M -65.02M
Other operating expenses 275.37M 245.51M 200.20M 191.26M 65.02M
Interest expense 24.22M 1.03M 3.84M 1.72M 0.05M
Tax provision 0.07M 2.07M 0.66M - -
Interest income 24.22M 33.32M 19.38M 4.30M -
Net interest income 24.22M 32.29M 15.40M 2.58M -
Income tax expense 0.07M 2.07M 0.66M -2.58M -1.04M
Total revenue 22.29M 107.94M 110.32M 0.00M 0.00M
Total operating expenses 268.69M 240.32M 200.20M 191.26M 65.02M
Cost of revenue 6.68M 5.19M 2.04M - -
Total other income expense net 24.22M 32.29M 19.85M 2.58M 0.05M
Net income from continuing ops -228.93M -107.35M -129.53M -188.68M -64.97M
Net income applicable to common shares - - - -188.68M -64.97M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 603.99M 711.33M 825.13M 313.82M 128.78M
Other current assets 8.25M 11.94M 14.35M 12.03M 2.05M
Total liab 201.64M 256.54M 339.75M 108.86M 250.30M
Total stockholder equity 402.35M 454.79M 485.38M 204.95M -121.52M
Deferred long term liab - - - 4.56M 3.17M
Other current liab 91.05M 56.72M 18.30M 11.68M 13.51M
Common stock 0.06M 0.05M 0.05M 0.04M 0.00M
Capital stock 0.06M 0.05M 0.05M 0.04M 0.00M
Retained earnings -725.76M -496.83M -389.48M -318.79M -130.11M
Other liab - - - - 1.90M
Other assets 442.40M - 11.77M 7.06M 5.66M
Cash 80.26M 105.68M 394.58M 64.18M 104.62M
Total current liabilities 104.20M 125.41M 118.24M 56.69M 14.85M
Current deferred revenue - 59.06M 50.53M - -
Net debt 16.00M -51.60M -296.96M 23.95M -104.62M
Short term debt 7.58M 7.54M 46.78M 35.96M -
Short long term debt total 96.26M 54.08M 97.62M 88.13M -
Other stockholder equity 1127.21M 950.72M 874.26M 523.92M -20.28M
Property plant equipment - - - - 10.32M
Total current assets 462.18M 599.31M 716.36M 266.86M 112.81M
Long term investments 69.72M 38.28M 27.17M - -
Net tangible assets - - - 204.95M -121.52M
Short term investments 370.07M 481.70M 307.43M 190.66M 73.78M
Net receivables 3.60M - - - -
Accounts payable 5.58M 2.10M 2.62M 9.05M 1.33M
Accumulated other comprehensive income 0.84M 0.85M 0.55M -0.22M -0.02M
Non currrent assets other 69.47M 3.50M -97.00M 7.06M 5.66M
Non current assets total 141.81M 112.02M 97.00M 46.95M 15.97M
Capital lease obligations 51.92M 54.08M 97.62M 88.13M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 88.62M -183.04M -141.91M -117.67M -74.19M
Change to liabilities - - - 7.42M 0.97M
Total cashflows from investing activities 86.30M -183.04M -154.51M -117.67M -79.98M
Net borrowings -0.23M -39.85M -29.39M - -0.39M
Total cash from financing activities 98.53M -24.09M 279.16M 252.62M 118.45M
Change to operating activities - - - -2.97M 1.75M
Net income -228.93M -107.35M -70.69M -188.68M -64.97M
Change in cash -25.43M -290.60M 332.22M 35.65M -15.76M
Begin period cash flow 108.31M 398.90M 66.68M 31.03M 46.80M
End period cash flow 82.88M 108.31M 398.90M 66.68M 31.03M
Total cash from operating activities -210.26M -83.47M 207.57M -99.30M -54.24M
Issuance of capital stock 131.56M 0.00M 100.00M 259.83M 119.12M
Depreciation -1.76M 5.19M 2.04M 1.32M 1.04M
Dividends paid - - 271.40M - 119.12M
Sale purchase of stock 1.30M 1.16M 1.09M 0.00M -0.02M
Other cashflows from financing activities -38.42M 15.76M 8.85M 2.47M 118.86M
Change to netincome - - - 83.60M 6.97M
Capital expenditures 2.33M 13.43M 21.43M 2.28M 5.78M
Change in working capital -57.49M -30.78M 225.43M 4.45M 2.72M
Stock based compensation 77.89M 61.09M 41.79M 21.54M 6.75M
Other non cash items 0.04M -11.62M 9.01M 62.06M 0.21M
Free cash flow -212.59M -96.90M 186.15M -101.58M -60.02M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Arcellx Inc

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

800 Bridge Parkway, Redwood City, CA, United States, 94065

240 327 0630

https://www.arcellx.com

209

Name Title Year Born
Mr. Rami Elghandour Chairman, CEO & Pres 1979
Mr. Neeraj P. Teotia Chief Commercial Officer 1975
Dr. Christopher R. Heery M.D. Chief Medical Officer 1980
Ms. Michelle Lim Gilson Chief Financial Officer 1992
Mr. Michael Dombeck M.B.A. Chief Operating Officer NA
Mr. Narinderjeet Singh M.S. Chief Technical Officer 1972
Mr. David Tice Ph.D. Chief Scientific Officer 1971
Ms. Myesha Lacy VP of Investor Relations NA
Ms. Maryam Abdul-Kareem J.D., M.S. Gen. Counsel NA
Ms. Kate Aiken Chief People Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…